Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion protein

Abstract excerpt

Palivizumab was the first antiviral monoclonal antibody (mAb) approved for therapeutic use in humans, and remains a prophylactic treatment for infants at risk for severe disease because of respiratory syncytial virus (RSV). Palivizumab is an engineered humanized version of a murine mAb targeting antigenic site II of the RSV fusion (F) protein, a key target in vaccine development. There are limited reported...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Influenza Virus Research Studies
• Share to Respiratory viral infections research
• Share to Viral gastroenteritis research and epidemiology